Q-omics provides the consensus-scored FKBP1A profile across patient tissues and cancer cell-line models. FKBP1A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FKBP1A is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, FKBP1A protein abundance shows 21,644 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, HNSC, and PDAC as cancer lineages where FKBP1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FKBP1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FKBP1A survival associations across molecular data types. FKBP1A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FKBP1A RNA expression–survival associations across cancer types. High FKBP1A expression shows unfavorable associations in ACC, UVM, KIRP, LIHC, LUAD and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FKBP1A RNA expression.
This table summarizes FKBP1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FKBP1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FKBP1A shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, STAD, LIHC and BLCA. The HNSC box plot shows higher FKBP1A RNA expression in tumor versus normal tissue (log2 FC = +1.349, t-test p < 0.001).
This table shows molecular features associated with FKBP1A in patient tissues and cancer cell lines. In patient samples, FKBP1A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FKBP1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Lymphoma.
